We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current RCKT market cap is 309.21M. The company's latest EPS is USD -2.4016 and P/E is -0.02.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -67.38M | -73.71M | -69.42M | -62.69M | -64.39M |
| Net Income | -62.05M | -69.65M | -66.72M | -60.33M | -61.33M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -134.3M | -167.25M | -224.34M | -259.66M | -273.21M |
| Net Income | -139.7M | -169.07M | -221.86M | -245.6M | -258.75M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 499.44M | 446.41M | 393.69M | 527.7M | 471.07M |
| Total Liabilities | 57.94M | 61.78M | 63.92M | 64.47M | 58.93M |
| Total Equity | 441.5M | 384.64M | 329.77M | 463.23M | 412.14M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 590.82M | 497.02M | 551.81M | 566.34M | 527.7M |
| Total Liabilities | 87.31M | 42.3M | 62.12M | 73.77M | 64.47M |
| Total Equity | 503.52M | 454.72M | 489.69M | 492.57M | 463.23M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -56.86M | -110.68M | -162.78M | -209.72M | -55.79M |
| Investing | 35.03M | 90.66M | 169.58M | 131.71M | -58.04M |
| Financing | 1.18M | 2.71M | 2.89M | 185.74M | N/A |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -74.64M | -121.16M | -178.14M | -194.92M | -209.72M |
| Investing | -96.59M | 18.85M | -69.33M | -98.07M | 131.71M |
| Financing | 282.99M | 37.68M | 155.29M | 208.4M | 185.74M |
| Market Cap | 309.21M |
| Price to Earnings Ratio | -0.02 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.03 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | - |
| Shares Outstanding | 107.74M |
| Average Volume (1 week) | 3.88M |
| Average Volume (1 Month) | 8.15M |
| 52 Week Change | -86.80% |
| 52 Week High | 26.98 |
| 52 Week Low | 2.19 |
| Spread (Intraday) | 0.01 (0.35%) |
| Company Name | Rocket Pharmaceuticals Inc |
| Address |
300 delaware avenue wilmington, delaware 19801 |
| Website | https://www.rocketpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
